Etoricoxib Auxilto

Acute & chronic symptomatic treatment of OA & RA. Ankylosing spondylitis (AS); acute gouty arthritis & pain including primary dysmenorrhoea & minor dental procedures.

OA 30 or 60 mg once daily. Not to exceed 60 mg daily. RA & AS 60 mg once daily, may be increased to max: 90 mg daily. Acute pain & gouty arthritis, primary dysmenorrhoea Not to exceed 120 mg once daily for 8 days. Minor dental procedures Not to exceed 90 mg once daily for 8 days. Mild hepatic insufficiency (Child-Pugh 5-6) Not to exceed 60 mg once daily. Moderate hepatic insufficiency (Child-Pugh 7-9) Not to exceed 60 mg every other day.

May be taken with or without food.

Hypersensitivity. CHF (NYHA II-IV); increased risk of CV disease eg, ischaemic heart disease & stroke; uncontrolled HTN; active peptic ulceration or GI bleeding; inflammatory bowel disease. Developed signs of bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria after ASA or other NSAIDs. Severe hepatic dysfunction (Child-Pugh >9); estimated renal CrCl <30 mL/min. Pregnancy & lactation. Childn & adolescents <16 yr.

Discontinue use at 1st appearance of skin rash, mucosal lesions or any other sign of hypersensitivity; persistent abnormal LFTs are detected. Not a substitute for ASA in CV prophylaxis. Serious skin reactions eg, exfoliative dermatitis, SJS & TEN. Increased risk of thrombotic events eg, MI, stroke. History of serious GI events & other risk factors associated w/ PUD eg, alcoholism, smoking, corticosteroid therapy; cardiac failure, left ventricular dysfunction. Significant risk factors for CV events eg, HTN, hyperlipidaemia, DM; pre-existing oedema; peripheral arterial disease. May mask fever. Ensure adequate hydration prior to therapy. Monitor BP 2 wk after initiation & periodically thereafter. Monitor renal function in patients w/ pre-existing significant renal impairment, uncompensated heart failure or cirrhosis. Concomitant use w/ NSAIDs, other NSAIDs or ASA even at low doses; warfarin or other oral anticoagulants. May affect ability to drive & use machines. Not recommended in advanced renal disease (CrCl <30 mL/min). Not recommended in women of childbearing potential. Not to be used during pregnancy & lactation. Elderly ≥65 yr, debilitated patients.

Abdominal pain. Alveolar osteitis; oedema/fluid retention; dizziness, headache; palpitations, arrhythmia; HTN; bronchospasm; constipation, flatulence, gastritis, heartburn/acid reflux, diarrhea, dyspepsia/epigastric discomfort, nausea, vomiting, oesophagitis, oral ulcer; increased ALT & AST; ecchymosis; asthenia/fatigue, flu-like disease.

Increased prothrombin time INR w/ warfarin. Reduced effects of diuretics, ACE inhibitors, AIIAs. Increased rate of GI ulceration w/ low-dose ASA. Increased nephrotoxic effect of cyclosporin or tacrolimus. Increased lithium plasma levels. Increased risk of MTX-related toxicity & plasma conc. Increased ethinyl estradiol plasma conc. Increased conjugated estrogen exposure of conjugated estrogens/HRT. Increased digoxin toxicity. Decreased plasma conc w/ rifampicin. Concomitant use w/ drugs metabolised by sulfotransferases eg, salbutamol PO, minoxidil.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

M01AH05 - etoricoxib ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, coxibs.

B